IalurilNewlogo

HEALTHCARE PROFESSIONALS

Clinical Data

A non-antibiotic therapy for the effective prevention of recurrent Urinary Tract Infections (rUTIs) level 1b data1; referenced in the EAU guidelines**

..Damiano R et al. (2011)1

Patients (57 women (mean age: 34.8 years) with 3 or more UTIs (>10³ CFU/ml) within previous year) were randomised 1:1 to iAluRil (n = 28) or placebo (saline; n = 29);  3 patients were lost to follow-up. They then received treatment or placebo weekly for four weeks followed by monthly for 5 months. The instillations were left in the bladder for at least 2 hours before voiding.  No prophylactic antibiotics were given before, during or after instillations. Urinalysis and urine culture were carried out 3 days prior to instillations to check urine sterility. Follow-ups were carried out at month 1, month 3, month 6, month 9 and month 12. Patients were assessed for UTI status (midstream specimen of urine), storage and voiding. Patients also completed SF-36 QoL questionnaires at each follow-up.



The authors concluded that compared with placebo, iAluRil intravesical instillations significantly reduced UTI rate without severe side effects while improving symptoms and QoL over a 12-month period in patients with rUTI.

..Cicione A et al. (2014)2

A retrospective cohort multicentre study involving 7 European centres.  157 women (mean age 54.2 ± 4.1 years) with documented history of at least 3 episodes of uncomplicated UTIs with the isolation of >103 CFU/mL of an identified pathogen with clinical symptoms in the last 12 months were studied.

Patients received iAluRil weekly for 4 weeks then monthly for 5 months (a total of 9 instillations). 28% of patients received a different regimen due to further instillations up to 12 months. Instillations for positive urine culture was delayed in 23 cases (14.6%).

Following baseline data capture, patients were assessed at 1 month, 6 months and 12 months (18-month and 24-month assessments were also carried out but for the purpose of this summary have not been used as patient numbers reduced and treatment had stopped on/before 12 months). At every visit patients completed: Pelvic Pain and Urgency/Frequency Symptom Scale (PUF) and SF-36 QoL questionnaire. Urinalysis and urine culture were performed before each instillation and at each follow-up visit.

Results at 12 months:

89.35% reduction in mean UTI rate per person from 4.13 to 0.44 (p=0.01)

28.32% reduction in mean total PUF score from 20.09 to 14.4 (p=0.01)

29.93% reduction in mean total symptom score from 13.7 to 9.6 (p=0.01)

31.51% increase in mean QoL SF-36 score from 59.25 to 77.92 (p=0.01)

The authors concluded that:

“This study suggests that intravesical HA-CS administration is an effective and well tolerated non-antibiotic treatment option in women with rUTI.”

..Ciani O. et al (2016)3

The objective of the study was to compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management (antimicrobial/immunoactive prophylaxis/probiotics/ cranberry) in 276 adult women with recurrent urinary tract infections (RUTIs).

The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health related quality of life and healthcare resource consumption.

Results

 

The study showed that “bladder instillation of combined HA+CS may reduce the risk of bacteriologically confirmed recurrences compared with the current standard management” of RUTIs.

..Gugliotti G et al (2015)4

174 patients with recurrent bacterial cystitis, with at least three episodes of uncomplicated cystitis in the past year were analysed. All patients had clinical symptoms and/or positive culture for each episode (isolation of >103 colony-forming units of a uropathogen per millilitre of urine).

Two cohorts of patients were selected retrospectively.

98 patients had been treated with iAluRil weekly for 4 weeks and then monthly for 4 months. 76 patients had been treated with once daily antibiotic prophylaxis (sulfamethoxazole 200 mg plus trimethoprim 40 mg) for 6 weeks. There was no significant difference between the 2 groups in relation to age (mean 36.4 Vs 39.1 years respectively) and Body Mass Index (BMI).

Patients had been followed up at 1 month, 3 months, 6 months and 12 months post-treatment.

The authors concluded that “the intravesical instillation of HA + CS is more effective than long-term antibiotic prophylaxis for preventing recurrent bacterial cystitis.” “In conclusion, our data, although preliminary, show the validity of this new therapeutic option, which could permit us to avoid repeated and harmful use of antibiotic therapy.”

..De Vita D et al. (2012)5 / De Vita D et al (2018)6

28 women (60 ± 13 years) with rUTI in the previous 12 months were randomised to iAluRil weekly for 4 weeks, fortnightly for 1 month (n=14) or long-term antibiotic prophylaxis sulfamethoxazole 200mg and trimethoprim 40mg, once weekly for 6 weeks (n=14). 26 completed the follow-up at 12 months as 2 iAluRil patients were lost to follow-up.

Results

Patients treated with iAluRil showed a reduction in the number of cystitis (UTI) recurrences, significantly reduced at 12-month follow-up (p=0.02).

The long-term effects of iAluRil at 36 months after treatment (n=12) were then evaluated6. The authors concluded that ‘Intravesical instillation of hyaluronic acid/ chondroitin sulfate is an effective and well-tolerated non- antimicrobial treatment for patients with recurrent bacterial cystitis that provides sustained clinical benefits for up to 36 months after treatment.’

..Torella M et al (2013)7

The aim of this study was to assess whether intravesical therapy with HA and CS (iAluRil) is more effective than antibiotic therapy in reducing episodes and symptoms of rUTIs.  69 Patients were enrolled from 3 different centres. Each patient had a minimum of 2 uncomplicated UTIs in the previous 6 months or 3 uncomplicated UTIs in the previous 12 months. No patients had active UTIs. Patients were assigned to three groups (group A: fosfomycin, B: iAluRil or C: fosfomycin + iAluRil).

The authors concluded that “It is evident that the local administration of GAGs, in particular HA and CS, in the bladder is a critical factor in reducing urinary recurrent infections.”

References
**EAU guidelines 2018. http://uroweb.org/guideline/urological-infections/#3 (accessed November 2018)
1. Damiano R et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur. Urol. 59(4), 645-651 (2011)
2. Cicione A et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre study. Can Urol Assoc J. 2014; 8(9-10): E721-7
3. Ciani O. et al Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case–control study. BMJ open (2016)
4. Gugliotti G et al. Is Intravesical Instillation of Hyaluronic Acid and Chondroitin Sulfate Useful in Preventing Recurrent Bacterial Cystitis? A Multicentre Case Control Analysis. Taiwan J Obstet Gynecol 2015; 54(5): 537-540.
5. De Vita D et al. Effectiveness of Intravesical Hyaluronic Acid/Chondroitin Sulfate in Recurrent Bacterial Cystitis: a Randomized Study. Int Urogynecol J 2012; 23(12): 1707-1713.
6. De Vita D, et al. Long-term efficacy of intravesical instillation of hyaluronic acid/ chondroitin sulfate in recurrent bacterial cystitis: 36 months’ follow-up. Clin. and Exp. Obstet. & Gynecol. 2018 – CEOG XLV n.2
7. Torella M et al. Intravesical Therapy in Recurrent Cystitis: a Multi-Center Experience. J Infect Chemother 2013; 19(5): 920-925.

..Sherif H et al. (2018)8

The safety and efficacy of Intravesical hyaluronic acid (HA)/chondroitin sulfate (CS) in the treatment of refractory painful bladder syndrome was evaluated in 45 patients (6 males, 31 females) aged 22-37 years (mean age 30.7 years). All patients experienced symptoms for more than 1 year. Patients were excluded if they had bladder cancer, bladder stones, recurrent urinary tract infection, previous history of intravesical instillation HA/CS or anticancer drugs.

Methodology

Patients were given iAluRil weekly for 4 weeks and at 6, 8, 12 and 16 weeks afterwards.

Results

Thirty-seven patients (6 males, 31 females) completed the entire follow-up protocol of this study.

Conclusion

“Intravesical instillation with both hyaluronic acid/chondroitin sulfate in the treatment of refractory painful bladder syndrome is safe, effective and well tolerated by all patients with no recorded side effects.”

..Cervigni M et al. (2008)9

In this study, 23 women with IC/PBS, who had failed several previous oral treatments and/or intravesical instillations of hyaluronic acid (HA) 0.08%, were administered iAluRil weekly for 20 weeks then every 2 weeks for 4 weeks and then monthly for 3 months.

Of the 23 patients who entered the study, there was no dropout of patients during the treatment period and all completed the protocol. No cases of intolerance, side effects or complications were observed.

Patients were evaluated before treatment, monthly during treatment and at 5 months follow up using a range of patient questionnaires (i.e. O’Leary-Sant Interstitial Cystitis Symptom Index [ICSI] and Problem Index [ICPI], Pelvic Pain and Urgency/Frequency Patient Symptom Scale and Visual Analogue Scale for pain, frequency and urgency), complete urinalysis and urine culture, a 3-day voiding diary and a complete urodynamic study.

Results

The author’s concluded that “This promising study seems to offer an additional therapeutic option in patients with refractory PBS/IC.

..Cervigni M et al (2012)10

12 women (34 – 65 years (mean 52.6 years) were enrolled in the study. All patients had failed previous treatments: pentosan polysulfate, cimetidine and dimethyl sulphoxide (DMSO); 2 patients had also undergone intradetrusorial administration of botulinum toxin. No other alternative or interim treatments were prescribed during the 3 years follow-up period.

 

Patients were administered iAluRil weekly for 20 weeks, then every 2 weeks for 4 weeks and then monthly for 3 years. Follow-up visits were conducted at 9 months and 3 years. Follow-up evaluations consisted of: 3-day voiding diary, VAS and validated questionnaires (O’Leary-Sant Questionnaire and PUF).

Conclusion

The authors concluded that: “Intravesical instillations of HA 1.6 % and CS 2.0 % over a period of 9 months produced a sustained improvement in symptoms, which was still apparent at 3-year follow-up, in patients affected by PBS/IC unresponsive to previous treatments.”

..Cervigni M et al. (2017)11

This study compared the efficacy and safety of intravesical HA/CS (Ialuril®, IBSA) to dimethyl sulfoxide (DMSO) in 110 women with BPS/IC (mean age 50.24), where patients experienced pain and at least one other urinary symptom (i.e., urgency or frequency) for ≥6 months.

Patients were randomized 2:1 to iAluRil or DMSO. 74 patients were treated with iAluRil and 36 patients were treated with DMSO. Patients received weekly instillations for 13 weeks.

Primary endpoint:

  • Difference in VAS Pain scores from baseline to 6 months (follow-up).

Secondary endpoints:

  • Difference in VAS Pain scores from baseline to 3 months (end of treatment [EoT]);
  • Difference in urinary capacity and frequency, and O’Leary-Sant ICSI and ICPI, PUF and Euro QoL 5 Dimensions Questionnaire (EQ-5D) scores from baseline to 3 and 6 months.

At 6 months, 59 patients for iAluRil and 31 patients for DMSO completed the follow-up.  Adverse events were experienced in 30.56% of patients treated with DMSO and 14.86% of patients treated with iAluRil.

“Treatment with HA/CS appears to be as effective as DMSO with a potentially more favourable safety profile. Both treatments increased health related quality of life, while HA/CS showed a more acceptable cost-effectiveness profile.”

..Cocci A. et al. (2016)12

A pragmatic retrospective analysis from January 2010 to September 2015 in a tertiary referral centre to compare Cystistat (n = 145), iAluril (n = 54), and Whitmore Cocktail (bupivacaine 0.5% x40ml, hydrocortisone 100 mg, heparin 10,000 units, sodium chloride 0.9% x 1Oml) (n=50) for treatment of patients with bladder pain syndrome/interstitial cystitis (BPS/IC).

All patients had the same instillation protocol: weekly for 6 weeks, then fortnightly for 4 weeks, then monthly for 6 months. Patients satisfaction regarding self-administration, relief of symptoms, switch between instillations, changes in frequency of instillation were analysed.

100% of iAluRil patients did not need to switch to alternative treatments whereas 21% of patients on Cystistat and 22% of patients on Whitmore switched to iAluril. Only 7% of patients on iAluRil stayed on monthly instillations whereas 9% of patients started on Cystistat and 18% of patients started on Whitmore Cocktail stayed on monthly instillations. One patient on Whitmore Cocktail remained on weekly instillations for the length of the study period. No patients had adverse events.

The authors concluded that “All three instillations were effective in BPS/IC patients but iAluril was the most effective, there was less risk of switching to another drug with greater likelihood of resolution of symptoms at the end of the 6 weekly instillations, and it was the simplest for patients to self-administer”. In terms of cost- effectiveness we would recommend that patients are started on the Whitmore cocktail for 6 weeks and if not successful then they are switched to iAluril. Nonetheless iAluRil wasn’t the most expensive from the treatment choices”.

8. Sherif H et al. Safety and efficacy of Intravesical hyaluronic acid/chondroitin sulfate in the treatment of refractory painful bladder syndrome. Turk J Urol. 2018 Nov 21:1-6. doi: 10.5152/tud.2018.63600. [Epub ahead of print]
9. Cervigni M et al. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int. Urogynecol J. 19, 943-947 (2008).
10. Cervigni M et al. Intravesical Hyaluronic Acid and Chondroitin Sulfate for Bladder Pain Syndrome/Interstitial Cystitis: Long-term Treatment Results. Int Urogynaecol J 2012; 23(9): 1187-1192.
11. Cervigni M et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid (HA) and chondroitin sulfate (CS) versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourology and urodynamics 2017 Apr;36(4):1178-1186. doi: 10.1002/nau.23091. Epub 2016 Sep 21.
12. Cocci A. et al. Comparison of Cystistat, iAluRil, and Whitmore Cocktail for treatment of patients with bladder pain syndrome/interstitial cystitis. Poster presentation. EAU16, Munich, Germany, 11-15 March 2016

..Imperatore V et al. (2018)13

The charts of 20 patients (9 males and 11 females) with Bacillus Calmette-Guérin (BCG)-induced grade 2 (severe and/or > 48-hour cystitis according to the World Health Organisation [WHO]) chemical cystitis, who had failed at least 1 month of conventional therapies (quinolone antibiotics and anti-inflammatory agents), were reviewed.

Following suspension of BCG instillations, patients were treated weekly with iAluRil for 8 weeks. Patients’ charts were reviewed retrospectively. Data was collected at baseline which included demographics, patient recorded VAS score (1-10) for bladder pain and urgency, and functional bladder capacity and daytime urinary frequency which was measured using 3-day frequency/volume charts.  Follow-up data was collected at 8 weeks, 6 months and 1 year using a 3-day voiding diary and patient recorded VAS scores for urinary urgency and pain.

 

Chemical cystitis arose following a mean of 3 BCG instillations (range: 1-5). The authors concluded that intravesical instillation of iAluRil was well tolerated by all patients, with no side effects observed during treatment, and is an efficacious treatment for refractory BCG-induced chemical cystitis.

..Creta M et al. (2012)14 

15 patients with grade 2 (>48 hours) chemical cystitis following intravesical instillation of Bacillus Calmette-Guerin (BCG) and unresponsive to traditional therapy were treated with intravesical instillation of iAluRil weekly for 8 weeks. Outcome measures were mean voiding volume, urinary frequency, urgency and bladder pain, which were measured prior to treatment, at 8 weeks and at 6 months. This was done using a voiding diary and VAS with values ranging from 0-10 for urgency and pain.

After 8 weeks of weekly treatment:

51.5% reduction in VAS urgency;

42.2% reduction in VAS pain;

37.4% reduction in mean voids per 24 hours;

88.3% increase in mean urine volume per void.

The authors concluded that:

“Intravesical therapy with HA and CS provides a sustained improvement of urgency, pain, frequency and bladder capacity in patients with BCG-induced cystitis.”

13. Imperatore V et al, Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: Preliminary experience with one-year follow-up. Arch Ital Urol Androl. 2018 Mar 31; 90(1): 11-14.
14. Creta M et al. Intravesical instillation of hyaluronic acid and chondroitin sulfate for bacillus calmette-guerin induced chemical cystitis. Poster presentation P164, 85th SIU (Italian Society of Urology) 2012; October 21-24

..Gacci M et al. (2016)15

The efficacy and safety of hyaluronic acid and chondroitin sulfate (HA-CS) instillation in 80 consecutive men treated with RT for prostate cancer (PCa) as primary or adjuvant treatment was evaluated. 30 (37.5%) of these patients reported clinically relevant lower urinary tract symptoms (LUTS) and were enrolled in the study (mean age: 69.1 years).

Following RT, the 30 patients who reported clinically relevant LUTS and associated bother (ICSI and ICPI ≥3) were entered into the study. 10 men had received primary RT for PCa and 20 men had received adjuvant RT for PCa. 3 (10%) patients had low-risk PCa, 13 (43%) had intermediate-risk PCa and 14 (47%) had high-risk PCa. The mean radiation dose was 67 Gy (range 62-80 Gy). All patients reported ≥ grade 1 toxicity according to the Radiation Oncology Group.  Patients were treated with iAluRil, weekly for 4 weeks, then at weeks 6, 8 and 12.

HA-CS instillation significantly reduced postradiation LUTS (P < .001) and bother (P = .006) irrespective of age and clinical features, with full recovery of urinary bother.

..Giannessi C et al. (2014)16

23 male patients were studied, mean age 67.9, with BPS due to pelvic irradiation for locally advanced PCa (16 patients underwent radical prostatectomy and RT, and 7 underwent RT alone).

Patients underwent intravesical administration of iAluRil weekly for the first month, and on the 6th, 8th and 12th week subsequently.

Nocturia was assessed immediately after RT and at 12 weeks after the final iAluRil instillation using question 3 (Q3) of the ICSI which asks how often patients experience nocturia and question 2 (Q2) of the ICPI which asks how much of a problem the patient finds nocturia.

The authors concluded that iAluRil was effective in reducing the symptoms and associated bother of nocturia in patients with post radiation BPS. However, further randomized controlled trials are required to confirm the results of this study.

15. Gacci M et al. Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Post radiation Cystitis: Prospective Pilot Study. Clin Genitourin Cancer. Oct;14(5):444-449 (2016)
16. Giannessi C et al. Nocturia related to post bladder pain can be improved by hyaluronic acid chondroitin sulphate. Eur Urol Suppl. 2014; 13; e592

Jung Ki Jo et al. (2018)17

Publication

BJU Int. 2018 May 17. doi: 10.1111/bju.14392.
Effect of highly concentrated hyaluronic acid/chondroitin sulphate instillation on ureteric stent induced discomfort after ureteroscopic lithotripsy: a multicentre randomised controlled pilot study

Subjects

92 patients (49 men and 43 women) completed the study, 46 and 46 were in the treatment and control arms, respectively.

Methodology

Eligible patients, who received an indwelling ureteric stent after ureteroscopic lithotripsy for a first-time ureteric stone, were randomly allocated to receive intravesical instillation with highly concentrated hyaluronic acid (HA)/chondroitin sulphate (CS) or normal saline just after ureteric stent placement.

The HA/CS instillation was prophylactic for relief of ureteric stent-related symptoms.**

Just before stent removal on postoperative day 7, the patients completed the Ureteric Stent Symptom Questionnaire (USSQ), International Prostate Symptom Score (IPSS) QoL question, and a pain visual analogue scale (VAS).

Results

Compared with the control group, the treatment group had significantly lower USSQ urinary symptom domain scores (24.6 vs 32.5; P < 0.001), better IPSS QoL scores (3.5 vs 4.4, P = 0.018), and lower VAS pain scores (2.0 vs 3.2; P < 0.001). They also had lower total body pain subscores (16.7 vs 22.0; P = 0.01) and lower additional pain subscores due to urinary tract infections (2.1 vs. 3.2; P = 0.01) in the USSQ.

Conclusion
Highly concentrated HA/CS instillation improved ureteric stent-induced urinary symptoms. It also significantly reduced pain, at least in the short term. Moreover, it reduced the need for additional medication or procedures after stent placement.

***This study meets the current product indication, regarding restoration of the bladder GAG layer. However, the posology for the treatment was not respected.
17. Jo JK et al. Effect of highly concentrated hyaluronic acid/chondroitin sulphate instillation on ureteric stent-induced discomfort after ureteroscopic lithotripsy: a multicentre randomised controlled pilot study. BJU Int. 2018 May 17.
*One instillation of iAluRil should be given weekly for the first month, followed by one instillation every two weeks for the second month. In the following months, one instillation a month should be given until symptoms resolve to the satisfaction of both the clinician and patient. (iAluRil patient information leaflet)
TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk

Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
Revision reference – iAluRil_4__16/09/2019